03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
19:11 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Santen reports Phase I/II safety data for wet AMD candidate

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) reported data from a Phase I/II trial in 12 patients with wet age-related macular degeneration (AMD) refractory to VEGF inhibitors showing that single intravitreal injections of DE-122 (carotuximab, Ophthalmic TRC105)...
22:36 , Jan 5, 2018 |  BC Week In Review  |  Company News

Ambrx gets Chinese rights to Tracon's carotuximab

Cancer company Tracon Pharmaceuticals Inc. (NASDAQ:TCON) granted Ambrx Inc. (La Jolla, Calif.) exclusive rights to develop and commercialize carotuximab (IV TRC105) in China, Hong Kong, Macau and Taiwan for all indications excluding ophthalmology, which are...
18:57 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Tracon reports Phase Ib data for carotuximab in NSCLC

In October, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 8 evaluable patients with stage IV non-squamous non-small cell lung cancer (NSCLC) in a Phase Ib trial showing that carotuximab (IV TRC105) in combination with paclitaxel/carboplatin...
00:33 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Tracon completes enrollment in Ph IIb TRAXAR trial of TRC105 to treat RCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) completed enrollment of 150 patients with advanced or metastatic renal cell carcinoma (RCC) who failed 1 prior VEGF inhibitor in the Phase IIb TRAXAR trial comparing carotuximab (TRC105) plus Inlyta axitinib...
18:02 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Tracon reports Phase I/II data for TRC105 in HCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 24 evaluable patients with advanced hepatocellular carcinoma (HCC) in an NCI-led Phase I/II trial showing that IV TRC105 (carotuximab) every other week plus Nexavar sorafenib led to...
19:58 , May 5, 2017 |  BC Week In Review  |  Clinical News

Tracon's IV TRC105 misses primary in Ph II GBM trial

In February, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported top-line data from the Phase II portion of a Phase I/II trial to treat recurrent glioblastoma multiforme (GBM) showing that IV TRC105 (carotuximab) plus Avastin bevacizumab missed the...
02:19 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

IV TRC105: Ph III started

Tracon began the international Phase III TAPPAS trial to evaluate weekly IV TRC105 plus once-daily oral Votrient pazopanib vs. Votrient alone in 124 patients. The company has an SPA for the trial from FDA. Tracon Pharmaceuticals...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

IV TRC105: Phase Ib/II started

Tracon began an open-label, U.S. Phase Ib/II trial to evaluate IV TRC105 every other week plus Nexavar sorafenib in about 39 patients who have not received prior systemic therapy. Tracon Pharmaceuticals Inc. (NASDAQ:TCON), San...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

IV TRC105: Phase I/II started

Tracon began an open-label, U.S. Phase I/II trial to evaluate 10 or 15 mg/kg IV TRC105 every 2 weeks for 24 weeks in combination with oral Afinitor everolimus and oral Femara letrozole in...